{"nctId":"NCT00684554","briefTitle":"Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial","startDateStruct":{"date":"2007-12"},"conditions":["Opioid-Related Disorders","Heroin Dependence"],"count":20,"armGroups":[{"label":"Unobserved-at home","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Buprenorphine"]},{"label":"Observed","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Buprenorphine"]}],"interventions":[{"name":"Buprenorphine","otherNames":["Bup"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. DSM-IV criteria for current opioid dependence with physical dependence and are seeking treatment\n2. Recent opioid use\n3. Individuals must describe opioids as their primary drug of abuse.\n4. 18-65 years of age\n5. Able to give informed consent and comply with study procedures\n6. Financially able to receive treatment at AIM and obtain medication (e.g., Medicaid)\n\nExclusion Criteria:\n\n1. DSM-IV opioid dependence without physical dependence\n2. Any current Axis I psychiatric disorder(s) as defined by DSM-IV-TR that in the investigator's judgment are unstable or would be disrupted by study participation (e.g., psychosis, active suicidal or homicidal ideation).\n3. Individuals who are significant risk for suicide based on their current mental state or history.\n4. DSM-IV alcohol or benzodiazepine dependence with physiologic dependence.\n5. Pregnancy, lactation. Women must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study.\n6. Unstable physical disorder that might make participation hazardous.\n7. Individuals with a known allergy, sensitivity or adverse reaction to buprenorphine.\n8. Past life-threatening idiosyncratic severe opioid withdrawal reaction (e.g., psychosis, seizure)\n9. Current buprenorphine maintenance\n10. Current long-acting opioid use (e.g., methadone)\n11. Inability to read or understand the self-report assessment forms unaided","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit.","description":"The primary outcome will include a comparison of the proportion of patients successfully inducted one week after the initial primary care visit. Defined as in treatment, on Buprenorphine and withdrawal free.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Prolonged Withdrawal","description":"participants experiencing prolonged withdrawal beyond two days after buprenorphine induction","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Prolonged withdrawal"]}}}